4.7 Article

Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir

Journal

CLINICAL MICROBIOLOGY AND INFECTION
Volume 29, Issue 5, Pages 6550-6550000

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cmi.2023.01.002

Keywords

Clinical research/practice; Drug interaction; Immunosuppressant; Lopinavir/ritonavir; SARS-CoV-2/COVID-19; Solid organ transplantation

Ask authors/readers for more resources

This study reviewed the drug-drug interactions between tacrolimus and lopinavir/ritonavir in solid organ transplant recipients during the first wave of COVID-19. Prednisone monotherapy was used temporarily to avoid drug interactions and toxicity. No episodes of acute rejection were observed.
Objectives: To review the drug-drug interactions between tacrolimus and lopinavir/ritonavir in 23 patients who received solid organ transplant during the first wave of COVID-19 and to determine the efficacy as well as safety of prednisone monotherapy. Methods: Observational study performed between March and June 2020 in solid organ transplant recipients admitted with an established diagnosis of SARS-CoV-2 infection who received lopinavir/ritonavir (>= 2 doses). Once lopinavir/ritonavir therapy was initiated, calcineurin inhibitor treatment was temporarily switched to prednisone monotherapy (15-20 mg/d) to avoid drug-drug interactions and toxicity. After lopinavir/ritonavir treatment completion, immunosuppressive treatment was restarted with reduced doses of prednisone-tacrolimus (target minimum blood concentration -C-0- approximately 5 ng/ mL). Patients were observed for 3 months to confirm the absence of rejection. Results: The median time from discontinuation of tacrolimus to initiation of lopinavir/ritonavir was 14 hours (interquartile range [IQR], 12-15) and from discontinuation of lopinavir/ritonavir to resumption of tacrolimus 58 hours (IQR, 47-81). The duration of lopinavir/ritonavir treatment was 7 days (IQR, 5-7). Nine of the 21 (42.8%) patients on tacrolimus treatment had C-0 above the cutoff point after lopinavir/ ritonavir initiation, despite having been substituted with prednisone before lopinavir/ritonavir initiation. Three patients had very high concentrations (>40 ng/mL) and developed toxicity. No episodes of acute rejection were diagnosed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available